The Bovine Serum Albumin Market is estimated to be valued at USD 255 million in 2019 and is projected to reach a value of USD 304 million by 2025, growing at a CAGR of 3.0% during the forecast period. Factors such as the inexpensive and stable nature of bovine serum albumin as a protein standard, growing demand for blood-based products are some of the factors driving the growth of the market.
The North America region accounted for the largest share in the bovine serum albumin market. The growing livestock sector, the rising demand for red meat & its products, and the increasing rate of cattle slaughtering drive the growth of the bovine serum albumin market in the North American region.
The Asia Pacific region holds a range of opportunities for pharmaceutical firms and multinational drugmakers. In the Asia Pacific region, China is the largest market for pharmaceutical products. With the growing interest in health and welfare, the demand for pharmaceutical products is growing. This would help drive the growth of BSA in this region.
Leading companies are Thermo Fisher Scientific (US), Bio-Rad Laboratories, Inc (US), Merck KGAA (Germany), Itoham Yonekyu Holdings Inc (Japan),a Proliant Biologicals (US), Kraeber & Co Gmbh (Germany), Rockland Immunochemicals Inc (US), Rocky mountain biologicals (US), BelHealth investment partners, LLC (US), Bio-Techne Corporation (US), Prospec-Tany Technogene Ltd (Israel), LGC Group (UK), Promega Corporation (US), Biological Industries (Israel), and Serion GmbH (Germany).
